SEC EDGARSEP 31 min read$IRTC

Wilson Daniel G. sold $94K of IRTC

Wilson Daniel G. (Chief Financial Officer) sold 773 shares of iRhythm Holdings, Inc. (IRTC) at $121.83 on 2026-09-02.

Original reporting

SEC EDGAR · Wilson Daniel G.

Published Sep 3, 2026, 8:01 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 3, 2026, 8:02 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$IRTC

Bearish

medium confidence

Mentioned

$IRTC

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$IRTCBearishLow

Why it matters

The transaction is a primary disclosure but modest in size, likely causing limited price movement.

Market read

Small insider sale with low immediate trading relevance; may be noted by short‑term traders.

What to watch

Potential upcoming earnings or product news could be the real driver of price movement, not the insider sale.

Relevance 3/10Novelty 4/10Timing: post‑market filing

Background

Form 4 filing discloses insider transactions; this is the first public report of the CFO's sale.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$IRTCBearishMedium confidence

Context

CFO Wilson Daniel G. sold 773 shares of iRhythm Holdings at $121.83 each, total $94,174.59, reducing his stake to 34,887 shares.

Expected impact

Potential short-term dip of 0.5‑1% if market interprets sale as lack of confidence.

Evidence & confidence

The sale size is modest relative to float, but CFO exits can signal concerns; however, the amount is small enough to limit impact.

Market effects

Sector

Limited effect on digital health sector; similar insider sales have minimal sector impact.

Regional

No regional impact; company is US‑listed with niche market.

Global

Low global relevance; only affects IRTC shareholders.

Counterpoint

What could challenge this read

The sale may be routine portfolio rebalancing, not a confidence signal.

Key entities

company
iRhythm Holdings, Inc.
Digital health company providing cardiac monitoring solutions.
person
Wilson Daniel G.
Chief Financial Officer of iRhythm Holdings.

Read at source ← All news

SEP 14

$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

yahoo.com3 min

SEP 4

$IRTCMed

Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?

iRhythm Holdings (IRTC) reported Q2 2026 revenues of $224.2M, up 20.1% YoY, and raised full-year guidance to $880-$890M. Gross margin expanded to 72.8%, and adjusted EBITDA grew over 1,000 bps YoY. However, risks include reimbursement uncertainties, execution challenges, and an unresolved FDA warning letter.

tradingview.com3 min

SEP 4

$PODDMedAI 8/10

Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks

Insulet (PODD) reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next quarter's guidance. Peers iRhythm (IRTC), ResMed (RMD), and DexCom (DXCM) also reported earnings, with mixed market reactions. PODD is down 11.6% since reporting, while DXCM is up 20.6%.

finance.yahoo.com3 min

SEP 3

$IRTCMed

Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks

iRhythm (IRTC) reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates. ResMed (RMD) reported $1.46B in revenue, up 8.6% YoY, in line with expectations. Insulet (PODD) reported $801.7M in revenue, up 23.5% YoY, beating estimates but missing guidance. IRTC stock is down 4.4%, RMD up 3.4%, and PODD down 11.6% since reporting.

finance.yahoo.com2 min

AUG 16

$IRTCMedAI 9/10

iRhythm (IRTC) Q2 2026 Earnings Call Transcript

iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.

aol.com6 min

AUG 11